KY 0118
Alternative Names: KY-0118Latest Information Update: 07 Feb 2025
Price :
$50 *
At a glance
- Originator Novatim Immune Therapeutics (Zhejiang)
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements; Programmed cell death 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 07 Feb 2025 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) in China (IV), prior to February 2025 (Novatim Immune Therapeutics (Zhejiang) pipeline, February 2025)
- 07 Feb 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Combination therapy) in USA (IV), prior to February 2025 (Novatim Immune Therapeutics (Zhejiang) pipeline, February 2025)
- 07 Feb 2025 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease) in USA (IV), prior to February 2025 (Novatim Immune Therapeutics (Zhejiang) pipeline, February 2025)